NephroGenex (NRXGQ) Stock Price, News & Analysis

Company Overview

NephroGenex, Inc. (OTCMKTS: NRXGQ) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for kidney and related disorders. Founded in 1999 and headquartered near Denver, Colorado, NephroGenex leverages a proprietary discovery platform to identify and advance candidates that address acute and chronic kidney injury, an area of significant unmet medical need. The company’s research efforts aim to provide new treatment options for patients vulnerable to nephrotoxicity and progressive renal decline.

The company’s lead candidate, NephroCap, is under investigation for its potential to mitigate cisplatin-induced nephrotoxicity in oncology patients. In parallel, NephroGenex is advancing NGX-250, a novel small-molecule inhibitor designed to reduce inflammatory pathways associated with acute kidney injury in hospitalized individuals. Earlier-stage programs include NGX-350, intended to preserve renal function following ischemia-reperfusion events, and NGX-600, which targets fibroblast activation in chronic kidney disease. Select candidates have progressed through preclinical studies, with several entering Phase 1 and Phase 2 clinical trials.

NephroGenex conducts its research and development programs through collaborations with contract research organizations and academic centers across North America and Europe. These partnerships enable the company to access specialized laboratory facilities, diverse patient populations, and regulatory expertise needed to accelerate program timelines. In addition to its Colorado-based labs, NephroGenex works closely with global clinical sites to advance multi-center trials and engage with key opinion leaders in nephrology.

The company is led by a team of experienced biotechnology and pharmaceutical executives, supported by scientific advisors from leading academic institutions. Under the guidance of its Chief Executive Officer and Chief Scientific Officer, NephroGenex continues to refine its pipeline, pursue regulatory designations and explore strategic collaborations. The company remains focused on translating its early-stage innovations into safe and effective therapies that protect and restore kidney health.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 2,000 shs
• Average Volume: 26,223 shs
• Market Capitalization: $36 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NRXGQ Stock Analysis - Frequently Asked Questions

How do I buy shares of NephroGenex?

Shares of NRXGQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Manufacturing
• Industry: Electronic Computer Manufacturing
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:NRXGQ
• Previous Symbol: NASDAQ:NRX
• CIK: 1338095
• Web: www.nephrogenex.com
• Phone: +1-609-5538887
• Fax: N/A
• Employees: 1,700
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 12,950,000
• Free Float: N/A
• Market Cap: $36 thousand
• Optionable: Not Optionable
• Beta: N/A